| Business

Become a contributor

Bookmark Econotimes

| Business

SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO

DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins

Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million

Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing

SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates

Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks

Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil

Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains

Washington Post Publisher Will Lewis Steps Down After Layoffs

SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

Anta Sports Expands Global Footprint With Strategic Puma Stake

Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate

Samsung Electronics Shares Jump on HBM4 Mass Production Report

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

©Econometrics LLC . All Rights Reserved.

Teligent, Inc. to Present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday March 20, 2018

Tuesday, March 13, 2018 8:30 PM UTC

BUENA, N.J., March 13, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 28^th Annual Healthcare Conference. The Conference is taking place March 20-21, 2018 at the Westin Grand Central, New York, NY.

Jason Grenfell-Gardner, President and CEO and Damian Finio, Chief Financial Officer of Teligent, Inc. will present on Tuesday March 20^th at 8:00 a.m. ET.

The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 30 days.

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Sydney Braces for Pro-Palestine Protests During Israeli President Isaac Herzog’s Visit

Israel Approves West Bank Measures Expanding Settler Land Access

Japan’s Prime Minister Sanae Takaichi Secures Historic Election Win, Shaking Markets and Regional Politics

Trump Congratulates Japan’s First Female Prime Minister Sanae Takaichi After Historic Election Victory

Anutin’s Bhumjaithai Party Wins Thai Election, Signals Shift Toward Political Stability

Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances

Ghislaine Maxwell to Invoke Fifth Amendment at House Oversight Committee Deposition

Samsung Electronics Shares Jump on HBM4 Mass Production Report

Trump Administration Appeals Court Order to Release Hudson Tunnel Project Funding

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Teligent, Inc. to Present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday March 20, 2018

Editor's Picks

Welcome to EconoTimes